1784.TWO(1784.TWO)

$58.00—Stale · unknown old

Ask SA Chart

1784.TWO(1784.TWO)

TWO • Last print unknown ago

$58.00—Stale · unknown old

Ask SA Chart Studio

1784.TWO(1784.TWO)

1784.TWO

9/19/26

BIONET (1784.TWO)

Saturday

5:59 AM

ThesisRecent strategic partnerships and anticipated regulatory approvals are likely to enhance revenue growth prospects, shifting investor sentiment positively.

Revenue Outlook

Metric	FY2025	FY2026E
Revenue	$1.2B	$1.3B
Rev. Growth	+1.2%	+7.8%
EPS	$1.02	$1.75
EPS Growth	-38.2%	+71.6%
P/E (fwd)	56.9×	33.1×

★ Analysts see FY2026 revenue reaching $1.3B — +7.8% growth in a single year.

The Bull Case for Growth

01BIONET's recent partnership with a leading hospital network in Taiwan is expected to increase test volume by 25% over the next year.
02The company is on track to receive FDA approval for a new molecular test, which could expand its market presence in the U.S. significantly.
03A recent survey indicates a 30% increase in demand for molecular diagnostics in the Asia-Pacific region, aligning with BIONET's strategic focus.
04Growth in molecular diagnostics due to increased health awareness
05Expansion of telehealth services driving demand for remote diagnostics
06Regulatory approvals for new diagnostic tests
07Partnership agreements with healthcare providers
08Market demand for molecular diagnostics in Asia-Pacific

FY2025 Snapshot

Revenue: $1.2B
Rev. Growth: +1.2%
Gross Margin: 55.3%
Op. Margin: -1.2%
Net Margin: 4.2%
Net Income: $51M
NI Growth: -38.6%
EPS: $1.02
1Y Return: -31.3%

1784.TWO Chart

My Notes

"Management highlighted, 'Our strategic partnerships position us to capitalize on the growing demand for diagnostics in Asia-Pacific.'"
Moat: BIONET's proprietary technologies and established relationships with healthcare providers create a moderate moat against competition.
growth - Investors are likely attracted to BIONET for its innovative product pipeline and potential for market expansion.
Rising interest rates could increase BIONET's financing costs for R&D projects…
Watch on earnings: Market share in molecular diagnostics, Regulatory approval timelines for new products, R&D expenditure as a percentage of revenue.

One Sentence Summary:

The bull case: BIONET is positioned for +7.8% growth on the back of bionet's recent partnership with a leading hospital network in taiwan is expected to increase test volume by 25%.

Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance

Metric

FY2025

FY2026E

P/E (fwd)

56.9×

33.1×

The Bull Case for Growth

01BIONET's recent partnership with a leading hospital network in Taiwan is expected to increase test volume by 25% over the next year.

02The company is on track to receive FDA approval for a new molecular test, which could expand its market presence in the U.S. significantly.

03A recent survey indicates a 30% increase in demand for molecular diagnostics in the Asia-Pacific region, aligning with BIONET's strategic focus.

04Growth in molecular diagnostics due to increased health awareness

05Expansion of telehealth services driving demand for remote diagnostics

06Regulatory approvals for new diagnostic tests

07Partnership agreements with healthcare providers

08Market demand for molecular diagnostics in Asia-Pacific

My Notes

"Management highlighted, 'Our strategic partnerships position us to capitalize on the growing demand for diagnostics in Asia-Pacific.'"

Moat: BIONET's proprietary technologies and established relationships with healthcare providers create a moderate moat against competition.

growth - Investors are likely attracted to BIONET for its innovative product pipeline and potential for market expansion.

Rising interest rates could increase BIONET's financing costs for R&D projects…

Watch on earnings: Market share in molecular diagnostics, Regulatory approval timelines for new products, R&D expenditure as a percentage of revenue.